Formulary guidance and transparency from P&T to point of care


Reality Check on Chronic Lymphocyctic Leukemia

Market access for chronic lymphocyctic leukemia (CLL) treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Under the pharmacy benefit, almost 48% of the lives under commercial formularies are covered with utilization management restrictions
  • Class Trends: The FDA has approved two biosimilars for Biogen and Genentech’s Rituxan (rituximab), and both are indicated for CLL. Teva Pharmaceuticals USA, Inc. and Celltrion, Inc.’s Truxima (rituximab-abbs) launched in November 2019, and Pfizer Inc.’s Ruxience (rituximab-pvvr), approved in July 2019, will launch in January 2020
  • Key Findings: There is good coverage for products treating CLL, although many plans do not have drug-specific policies for the older chemotherapy agents. Payers have written or are in the process of writing policies for the newer, more targeted agents

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.